Direct-to-Drug Screening Tool Allows for Precision Medicine in Multiple Myeloma
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
Multiple Myeloma
Addition of Isatuximab to Kd Deepens Responses and Extends PFS in R/R Multiple Myeloma
The majority of patients enrolled in this phase 3 trial had previously received both a proteasome inhibitor and an immunomodulatory agent.
Ixazomib Found Effective as a Maintenance Therapy in Patients With Newly Diagnosed MM Who Are Ineligible for Transplant
Ixazomib maintenance therapy prolonged PFS compared with placebo among patients with newly diagnosed MM who were not eligible for transplant.
All Oral Proteasome Inhibitor-Containing Regimen in Transplant-Ineligible Multiple Myeloma
Ixazomib, lenalidomide, and dexamethasone are all oral agents and each one has been approved by the FDA in the setting of multiple myeloma.
Risk of Thrombosis With Treatments for Newly Diagnosed Multiple Myeloma
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.
Early-Memory T-Cell Population May Predict CAR-T Efficacy in Several Hematological Malignancies
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
KRd Fails to Improve Outcomes Compared With VRd in Newly Diagnosed MM
Carfilzomib plus lenalidomide and dexamethasone failed to improve outcomes compared with bortezomib plus lenalidomide and dexamethasone among patients with newly-diagnosed MM.
Novel Triple Therapy With First-in-Class Selinexor Improves Outcomes in Multiple Myeloma
Researchers presented initial results from an ongoing, phase 3, randomized study of once-weekly SVd vs twice-weekly Vd after 1 to 3 prior anti-multiple myeloma regimens.
Deep and Durable Responses to Double Anti-BCMA, Single-Domain Antibody CAR-T Therapies Seen in RRMM
CAR-T therapy containing 2 anti-BCMA single-domain antibodies resulted in high response and PFS rates, according to phase 1b results.
Anti-BCMA CAR-T Deemed Effective in Heavily Pretreated, Refractory Multiple Myeloma
Anti-BCMA CAR T-cell therapy idecabtagene vicleucel demonstrated promising efficacy among patients with heavily pretreated and refractory MM.
-
Loading...
-
Loading...
Next post in ASCO 2020
